GlassScriptPhysician profile
Donna Lynn Casey
NPI 1689612749
$1,675.95
in general payments reported to CMS, 2019-2025
32 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.85 · 2020: $26.62 · 2021: $402 · 2022: $285 · 2023: $229 · 2024: $195 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909 · Entertainment: $33.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.80 |
| Entertainment | $33.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $228.62 | 2021-2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.15 | 2024-2025 | Ofev, Jascayd |
| Medtronic, INC. | $151.80 | 2024-2025 | Venaseal, O-Arm |
| Alcon Vision LLC | $118.55 | 2022 | |
| Optinose US, INC. | $114.68 | 2021 | |
| Pfizer INC. | $109.81 | 2021-2025 | |
| Abbvie INC. | $92.67 | 2021-2023 | Vraylar |
| Glaxosmithkline, LLC. | $87.61 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Biogen, INC. | $67.10 | 2021 | |
| Amgen INC. | $47.82 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $34.56 | 2021-2023 | Freestyle Libre 3 |
| Optos, INC. | $33.93 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Idorsia Pharmaceuticals US INC | $30.54 | 2022-2023 | Quviviq |
| Si-Bone, INC. | $30.17 | 2025 | |
| Sunovion Pharmaceuticals INC. | $29.87 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.25 | 2025 | Auvelity |
| Amarin Pharma, INC. | $23.92 | 2022 | |
| Lilly USA, LLC | $23.39 | 2025 | Kisunla |
| Alexion Pharmaceuticals, INC. | $20.14 | 2021 | |
| Genentech USA, INC. | $20.11 | 2021 | |
| Allergan, INC. | $19.85 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.29 | 2022 | |
| Sumitomo Pharma America, INC. | $19.00 | 2024 | Gemtesa |
| Novo Nordisk INC | $17.71 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.64 | 2021 | |
| Exact Sciences Corporation | $17.40 | 2023 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $16.80 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.00 | 2023 | Horizant |
| Acella Pharmaceuticals, LLC | $15.72 | 2023 | NP Thyroid 60 |
| Astellas Pharma US INC | $12.79 | 2023 | Veozah |
| Upsher-Smith Laboratories LLC | $12.64 | 2021 | |
| Eisai INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.